December 9, 2006 |
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
June 12, 2007 |
Drug maker Bristol-Myers Squibb Co. said Monday that it pleaded guilty to two counts of making false statements to the Federal Trade Commission regarding the firm's botched settlement with generic drug maker Apotex Inc. over the blood thinner Plavix. As a result, Bristol-Myers will pay a fine of $1 million, resolving a Justice Department probe.
September 4, 2002 |
Bristol-Myers Squibb Co. moved closer to Food and Drug Administration approval of the Abilify schizophrenia drug, which may be the company's next big product. The drug maker said it is in discussions with the FDA, which sent a letter indicating that the product may be approved after certain issues are resolved. The company didn't reveal what concerns the FDA raised in the letter. Bristol-Myers said it expects FDA approval of Abilify this year.
August 9, 2006 |
Sanofi-Aventis and Bristol-Myers Squibb Co. are facing generic competition in the U.S. for their top-selling Plavix blood-thinning pill five years earlier than planned. Apotex Inc., a closely held Canadian maker of generic drugs, said it started shipping cheaper copies Tuesday. Plavix is the world's second-best-selling pill. Sanofi and Bristol-Myers lost a bid Monday in U.S. court to block the sales. At stake for Paris-based Sanofi and New York-based Bristol-Myers is $6.